The present invention relates to the therapy of ionizing radiation-induced disorders and in particular to agents for use in said therapy.
This application includes an electronically submitted sequence listing in .txt format. The .txt file contains a sequence listing entitled “19828-365-Sequence_Listing_ST25.txt” created on Nov. 27, 2019 and is 2.94 kilobytes in size. The sequence listing contained in this .txt file is part of the specification and is hereby incorporated by reference herein in its entirety.
Connexins (Cx), or gap junction proteins, are structurally related transmembrane proteins that assemble to form hemichannels and gap junctions that function as channels connecting neighbouring cells. They are ubiquitous proteins expressed in almost all vertebrate cells, are crucial for normal organ and tissue function and play prominent roles in the normal functioning of the heart, brain, liver, vascular system, and other organs and tissues. Endothelial cells, the interior lining of blood vessels and cardiac valves, express three main Cx isotypes, namely Cx37, Cx40 and Cx43. However, gap junctions and hemichannels are an underexplored pharmacological target; among others, because of the limited possibilities of specifically targeting hemichannels versus gap junctions. Moreover, systemic administration of drugs that inhibit gap junctions have considerable potential side effects on cardiac pump function and may disturb heart rhythm. Connexins in cardio- and neurovascular health/disease and therapeutic strategies targeting connexins were recently reviewed by Leybaert et al. (LEYBAERT, Luc, et al. Connexins in cardiovascular and neurovascular health and disease: pharmacological implications. Pharmacological reviews, 2017, 69.4: 396-478.) and Laird and Lampe (LAIRD, Dale W.; LAMPE, Paul D. Therapeutic strategies targeting connexins. Nature Reviews Drug Discovery, 2018, 17.12: 905.).
Connexins assemble in the cell membrane to form hemichannels. In turn, the docking of two connexin hemichannels of adjacent cells leads to the formation of a gap junction. The latter functions as a channel connecting neighbouring cells. ‘Free’ hemichannels not incorporated into gap junctions are normally closed, but may open under conditions that include ischemia, inflammation, electrical stimulation, exposure to reactive oxygen species or nitric oxide, and elevation of the intracellular cytoplasmic calcium concentration.
Uncontrolled opening of hemichannels, a condition sometimes referred to as “leaky hemichannels”, has been reported in various different pathological conditions including cardiac ischemia/reperfusion, stroke, spinal cord injury, pain hypersensitivity, retinal disease, delayed wound healing and inflammatory diseases. In particular, increased hemichannel opening may lead to the release of essential signaling and metabolic molecules from the cell with a molecular weight of up to about 1.5 kDa, thereby compromising cell function. Examples of released molecules are ATP, NAD+, glutamate, prostaglandin E2 and others. Increased hemichannel opening also facilitates substance entry into the cell, as is the case for sodium and calcium ions, leading to calcium ion overload. Because hemichannels are poorly-selective channels, they pass charge-carrying ions and thereby conduct current over the membrane that affects electrical cell functioning, as is the case in the heart.
Breast cancer represents one of the most common malignancies in women with over 1.4 million cases diagnosed annually worldwide. Adjuvant radiotherapy is a standard therapy for breast cancer treatment after conservative surgery and mastectomy. While radiotherapeutic treatment consists of targeted and precise application of radiation beams, exposure of surrounding healthy tissue is inevitable. Exposure of healthy tissue, in particular the heart, to ionizing radiation (IR) often increases the risk for the development of cardiovascular diseases (CVD), especially atherosclerosis. Although modern radiotherapy techniques reduce the volume of the heart and major coronary vessels exposed to high doses of IR, some exposure is often unavoidable, especially in the case of left-sided breast cancer, in which case the dose received by the heart area is in the order of about 6.6 Gy (compared to 2.9 Gy for right-sided breast cancer). A population-based case-control study in women who underwent radiotherapy for breast cancer indicated a significant increase of 7.4% in the rate of major coronary events (i.e. myocardial infarction, coronary revascularization, or death from ischemic heart disease) per increase of 1 Gy in the cardiac exposure dose, without apparent threshold.
In addition to breast cancer, exposure of the cardio- and/or neurovascular system to IR may occur during cancer radiotherapy for e.g. head-and-neck cancer, Hodgkin's lymphoma and oesophageal cancer. Although radiotherapy is an effective treatment for most tumor types, growing evidence indicate a link between IR exposure—at high and medium doses (>0.5 Gy) but also at much lower doses—and, for example, atherosclerosis development. Atherosclerosis is a progressive inflammatory disease of the arterial wall that is initiated with damage to the vascular endothelial cells. In addition, in the brain, IR induces the breakdown of the blood-brain barrier through its effects on brain microvascular endothelial cells, which are most vulnerable to radiation exposure. Moreover, cellular and molecular changes induced by ionizing radiation occur not only in directly irradiated cells, but can also be transferred to adjacent non-irradiated cells; a process known as ‘the bystander effect’. However, the underlying cellular and molecular mechanisms for these conditions have not been fully understood, possibly resulting in improper radiation protection.
As such, there is a need for radioprotective measures to protect the cardio- and/or neurovascular system of a treated patient from radiation-induced secondary health effects. However, at present, there is no radioprotective compound that is clinically approved therefor.
It is an object of the present invention to provide good agents for use in the therapy of ionizing radiation-induced disorders and/or the therapy of atherosclerosis. It is a further object of the present invention to provide good uses and methods for use of said agents. This objective is accomplished by agents, pharmaceutical compositions and methods according to the present invention.
It is an advantage of embodiments of the present invention that an effective therapy for ionizing radiation-induced diseases can be formulated. It is a further advantage of embodiments of the present invention that good medical targets for said therapy, as wells as effective agents for targeting said targets, can be identified.
It is an advantage of embodiments of the present invention that a variety of ionizing radiation-induced diseases can be addressed, including cardiovascular disorders (e.g. atherosclerosis), neurovascular disorders (e.g. disturbed blood-brain barrier function) and/or neurodegenerative disorders.
It is an advantage of embodiments of the present invention that side effects of radiotherapy (e.g. thoracic or head-and/or-neck radiotherapy) can be mitigated and/or prevented. It is a further advantage of embodiments of the present invention that this can be achieved both for a patient of the radiotherapy as for assisting medical personnel.
It is an advantage of embodiments of the present invention that a particular isotype (e.g. Cx43) of connexin proteins and/or hemichannels and/or gap junctions can be targeted in a specific manner with respect to another isotype thereof.
It is an advantage of embodiments of the present invention that connexin hemichannels can be targeted in a specific manner with respect to connexin gap junctions.
In a first aspect, the present invention relates to an agent for inhibiting a connexin protein, connexin hemichannel or connexin gap junction, for use in the therapy of one or more ionizing radiation-induced disorders.
In embodiments, at least one of the one or more ionizing radiation-induced disorders may be a cardiovascular disorder, a neurovascular disorder or a neurodegenerative disorder.
In embodiments, the ionizing radiation-induced disorder may be an ionizing radiation-induced atherosclerosis.
In embodiments, the therapy may be for reducing side-effects from a radiotherapy.
In embodiments, the radiotherapy may be a thoracic radiotherapy or a head-and/or-neck radiotherapy.
In embodiments, the connexin protein may be a Cx43.
In embodiments, the connexin hemichannel may be a Cx43 hemichannel.
In embodiments, the connexin gap junction may be a Cx43 gap junction.
In embodiments, the agent may be for inhibiting the connexin hemichannel in a specific manner with respect to a corresponding connexin gap junction.
In embodiments, the agent may be a connexin-targeting molecule or a hemichannel inhibitor.
In embodiments, the agent may be a Gap19-based compound, an L2-based compound or a peptide5-based compound.
In a second aspect, the present invention relates to an agent for inhibiting a connexin protein, connexin hemichannel or connexin gap junction, for use in the therapy of an atherosclerosis.
In preferred embodiments, the agent may be for inhibiting the connexin hemichannel.
In a third aspect, the present invention relates to a pharmaceutical composition comprising an agent according to any embodiment of the first or second aspect or a pharmaceutical composition.
In embodiments, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
In embodiments, any feature of any embodiment of the third aspect may independently be as correspondingly described for any embodiment of any of the other aspects.
In a fourth aspect, the present invention relates to a method of therapy of an ionizing radiation-induced disorder, comprising: (a) inhibiting a connexin protein, connexin hemichannel or connexin gap junction in a subject, and (b) exposing the subject to radiation; wherein step a is performed during and/or after step b.
In embodiments, step a may comprise administering an agent according to any embodiment of the first or second aspect or a pharmaceutical composition according to any embodiment of the third aspect.
In embodiments, the agent and/or pharmaceutical composition may be administered before and/or during and/or after the radiation exposure.
In a fifth aspect, the present invention relates to a use of an agent according to any embodiment of the first or second aspect in a method of therapy of an ionizing radiation-induced disorder.
In embodiments, the method of therapy may be a method of therapy according to any embodiment of the fourth aspect.
Particular and preferred aspects of the invention are set out in the accompanying independent and dependent claims. Features from the dependent claims may be combined with features of the independent claims and with features of other dependent claims as appropriate and not merely as explicitly set out in the claims.
Although there has been constant improvement, change and evolution of products and techniques in this field, the present concepts are believed to represent substantial new and novel improvements, including departures from prior practices, resulting in the provision of more efficient, stable and reliable products and techniques of this nature.
The above and other characteristics, features and advantages of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention. This description is given for the sake of example only, without limiting the scope of the invention. The reference figures quoted below refer to the attached drawings.
Error! Reference source not found. to
In the different figures, the same reference signs refer to the same or analogous elements.
The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes. The dimensions and the relative dimensions do not correspond to actual reductions to practice of the invention.
Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequence, either temporally, spatially, in ranking or in any other manner. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.
It is to be noticed that the term “comprising”, used in the claims, should not be interpreted as being restricted to the means listed thereafter; it does not exclude other elements or steps. It is thus to be interpreted as specifying the presence of the stated features, integers, steps or components as referred to, but does not preclude the presence or addition of one or more other features, integers, steps or components, or groups thereof. The term “comprising” therefore covers the situation where only the stated features are present and the situation where these features and one or more other features are present. Thus, the scope of the expression “a product comprising means A and B” should not be interpreted as being limited to products consisting only of components A and B. It means that with respect to the present invention, the only relevant components of the product are A and B.
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to one of ordinary skill in the art from this disclosure, in one or more embodiments.
Similarly, it should be appreciated that in the description of exemplary embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects. This method of disclosure, however, is not to be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment. Thus, the claims following the detailed description are hereby expressly incorporated into this detailed description, with each claim standing on its own as a separate embodiment of this invention.
Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention, and form different embodiments, as would be understood by those in the art. For example, in the following claims, any of the claimed embodiments can be used in any combination.
In the description provided herein, numerous specific details are set forth. However, it is understood that embodiments of the invention may be practised without these specific details. In other instances, well-known methods, structures and techniques have not been shown in detail in order not to obscure an understanding of this description.
The following terms are provided solely to aid in the understanding of the invention.
As used herein, and unless otherwise specified, a disorder or medical disorder is an abnormal physical or mental condition of a subject. ‘Disorder’ therefore encompasses the following terms: disease, illness, medical condition, pathology, syndrome, complication, sequela, etc. The disorder may in general be short or long-term and symptomatic or asymptomatic.
As used herein, and unless otherwise specified, a subject is a human or animal being. The subject may, for example, be a patient, e.g. in an ionizing radiation treatment (which may be completed, ongoing or to be performed), but may likewise be medical personnel (e.g. a doctor, nurse or operator).
As used herein, and unless otherwise specified, an agent or pharmaceutical agent is a substance or compound having a pharmaceutical effect. The agent may, for example, be an inorganic molecule, an organic molecule, a biomolecule (e.g. a peptide or protein) or a supramolecular assembly thereof; the agent may range in size from a small molecule to a macromolecule.
As used herein, and unless otherwise specified, when reference is made to a connexin hemichannel reference is made to a ‘free’ hemichannel which is not incorporated into a gap junction.
As used herein, and unless otherwise specified, when reference is made to a hemichannel or gap junction of a particular connexin isotype, it is meant that said hemichannel or gap junction at least comprises, and preferably consists of, the corresponding connexin proteins of that isotype. For example, a Cx43 hemichannel comprises at least one Cx43 protein and preferably consists of six Cx43 proteins; in other words, the Cx43 hemichannel may be a heteromeric or homomeric Cx43 hemichannel.
In a first aspect, the present invention relates to an agent for inhibiting a connexin protein, connexin hemichannel or connexin gap junction, for use in the therapy of one or more ionizing radiation-induced disorders.
It was surprisingly realized within the present invention that connexins are involved in a variety of different ionizing radiation-induced secondary health effects. For example, the expression of Cx43, the most abundant connexin isotype in the human body, increases in response to ionizing radiation. Moreover, gap junctional cell-cell coupling as well as hemichannel opening increases, which collectively leads to disturbed cell-cell communication. An increase of gap junctional coupling enhances the propagation of cell death from dying cells to intact living cells by a mechanism of bystander cell death. Increased hemichannel opening results in ATP release that enhances inflammation, facilitates cellular Ca2+ overload, enhances cell death and leads to premature cell senescence. Combined, these effects act at the cellular as well as intercellular level, which may lead to ionizing radiation-induced disorders, including cardiovascular, neurovascular and neurodegenerative disorders. Crucially, counteracting hemichannel opening suppresses both cellular and intercellular levels of negative impact of radiation exposure. This is schematically depicted in
In general, the connexin may be of any isotype. There are 20 known connexins in mice and 21 in humans, which all form hemichannels as well as gap junctions. These distinct hemichannel isotypes can in principle all contribute, for example, to ATP release and calcium entry into the cells. It may then be expected that most, if not all, connexin isotypes hemichannels and/or gap junctions play a functional role in the cells and/or bodies where they are present. By functional role, it is here meant that the hemichannels and/or gap junctions can open and/or close under defined and realistic conditions for a particular cell type. Taking this notion into account, for example for connexin hemichannels, evidence for a functional role is presently available for several, but not yet all, connexins known. In particular, there is well-documented evidence available for a functional role of Cx43 and Cx26 hemichannels. For Cx30, Cx30.2, Cx32, Cx40 and Cx46 there is evidence, but less extensive than for Cx43 and Cx26. For Cx36, Cx37, Cx45, Cx45.6, Cx50 and Cx56 there is limited evidence available. For other connexins, the evidence is currently still sparse or absent. That said, the research on this topic is presently not concluded and it is reasonably believed that further additional evidence and functional roles for other connexins will still be found.
In preferred embodiments, the connexin protein may be a Cx43 protein, and/or the connexin hemichannel may be a Cx43 hemichannel, and/or the connexin gap junction may be a Cx43 gap junction. In other preferred embodiments, the connexin protein may be a Cx37, and/or the connexin hemichannel may be a Cx37 hemichannel, and/or the connexin gap junction may be a Cx37 gap junction. Cx43 (and to a lesser extent Cx37) proteins, hemichannels and gap junctions are particularly suitable targets, as described extensively in examples 1-3 (cf. infra). For Cx37, as set out in example 3, it had been expected that endothelial Cx43 KO in C57BL/6 Cx43fl/fl:Tie2-Cre mice would reduce bystander effects. However, because Cx37 displays compensatory increased expression, protection is masked suggesting that Cx37 also has bystander promoting effects and is therefore also an interesting target.
In embodiments, inhibiting a connexin protein may comprise inhibiting the expression of said connexin protein and/or inhibiting the formation of a connexin hemichannel or connexin gap junction therefrom. In embodiments, inhibiting a connexin hemichannel or connexin gap junction may comprise inhibiting the formation thereof and/or blocking or closing said hemichannel or said gap junction.
In embodiments, at least one of the one or more ionizing radiation-induced disorders may be a cardiovascular disorder, a neurovascular disorder, a neurodegenerative disorder or a dermal disorder. The disorder may, for example, be an inflammatory disease, cardiac ischemia/reperfusion, stroke, spinal cord injury, pain hypersensitivity, retinal disease, delayed wound healing, mental disorder (e.g. depression), etc. In preferred embodiments, the one or more radiation-induced disorders may be an ionizing radiation-induced atherosclerosis.
In embodiments, the therapy may comprise mitigation and/or prevention of one or more ionizing radiation-induced disorders. In embodiments, the radiation inducing the one or more disorders may be a medical intended radiation (e.g. as part of a radiation therapy), a medical non-intended radiation (e.g. a tissue surrounding a targeted area), an accidental radiation (e.g. due to a nuclear spill or accident) or an occupational radiation (e.g. as part of normal occupational handling). As such, e.g. in a radiotherapy, the one or more disorders may arise due to exposure of a targeted tissue to radiation or of an untargeted (e.g. surrounding) tissue in a patient, or exposure of an operator or assisting personnel. In embodiments, the therapy may be for reducing side-effects from a radiotherapy. In embodiments, the radiotherapy may be a thoracic radiotherapy or a head-and/or-neck radiotherapy (e.g. a brain radiotherapy).
In embodiments, the agent may be for inhibiting a first isotype (e.g. Cx43) of connexin protein, connexin hemichannel and/or connexin gap junction in a specific manner with respect to a second isotype (e.g. Cx37 or Cx40) of connexin protein, connexin hemichannel and/or connexin gap junction. Targeting specific connexin isotypes advantageously allows addressing selectively only those connexin isotypes which are involved in a particular disorder, thereby reducing the risk of side effects (e.g. which would occur when targeting other connexin isotypes which are not involved in the targeted disorder).
In embodiments, the agent may be for inhibiting one or more connexin hemichannels in a specific manner with respect to one or more connexin gap junctions (i.e. of the same or a different isotype). Gap junctions in particular fulfil important physiological functions and systemic administration of agents that inhibit gap junctions have considerable potential side effects, e.g. on cardiac pump function and heart rhythm. One, less preferred, strategy for reducing the above side effects may be to administer the agent locally (e.g. only to a targeted tissue). However, the risk of these side effects can be also advantageously be reduced significantly by targeting hemichannels specifically (i.e. with respect to gap junctions). This can then advantageously allow administering the agent in a broad manner (e.g. throughout the body). Moreover, in several cases, dysfunctional (e.g. leaky) hemichannels are the main cause of a particular disorder, more so than dysfunctional gap junctions. As such, it is then also for that reason advantageous to target hemichannels specifically.
In embodiments, the agent may be for inhibiting the connexin hemichannel in a specific manner with respect to a corresponding connexin gap junction (i.e. of the same isotype). For example, the agent may be for inhibiting Cx43 hemichannels specifically with respect to Cx43 gap junctions.
In embodiments, the agent may be a connexin-targeting molecule (e.g. a small molecule) or a hemichannel inhibitor. In embodiments, the agent may be a connexin mimetic peptide. In embodiments, the agent may be selected from carbenoxolone, a Gap19-based compound, a Gap26-based compound, an L2-based compound and a peptide5-based compound. Such a compound may, for example, be Gap19 (or Gap26, L2 or peptide5) as such, or may comprise or be derived from Gap19 (or Gap26, L2 or peptide5) fused to a membrane translocation sequence (e.g. TAT-Gap19). The membrane translocation sequence may advantageously facilitate cellular entry of the agent. Of the above, Gap19-based, L2-based and petide5-based compounds may be particularly preferred, as these can, for example, block Cx43 hemichannels in a specific manner. Gap junctions and hemichannels are typically composed of the same connexin building blocks; as a result, most substances that inhibit hemichannels also inhibit gap junctions. Nevertheless, agents have been identified which target hemichannels specifically with respect to gap junctions. For instance, peptides corresponding to certain sequences on the intracellular loop of a connexin (e.g. Cx43) have been found to specifically inhibit hemichannels while preserving gap junctional function. Examples of such peptides are Gap19 (a nonapeptide) and L2 (a 26 amino acid sequence that includes the Gap19 motif). L2 furthermore prevents gap junction closure, extending its potential effect spectrum to keeping Cx43 hemichannels closed and enhancing Cx43 gap junctional functions. Peptide5 is another interesting peptide in this respect, inhibiting hemichannels at low concentrations and hemichannels and gap junctions at higher concentrations. Peptide5 is currently believed to target not only Cx43 but also others connexin isotypes.
In embodiments, a dosage of the agent may be from 5 to 50 mg/kg, preferably between 10 and 40 mg/kg, yet more preferably between 15 and 35 mg/kg, most preferably between 20 and 30 mg/kg; such as 25 mg/kg. Such a relatively high dosage may be particularly relevant when the agent is a peptide (e.g. Gap19, such as TAT-Gap19), since the pharmaceutical activity of peptides is typically lower than for smaller molecules.
In embodiments, any feature of any embodiment of the first aspect may independently be as correspondingly described for any embodiment of any of the other aspects.
In a second aspect, the present invention relates to an agent for inhibiting a connexin protein, connexin hemichannel or connexin gap junction, for use in the therapy of an atherosclerosis.
It was surprisingly found within the present invention that connexins play a role in the pathology of atherosclerosis (both ionizing radiation-induced or not). Although healthy vascular endothelial cells mainly express Cx37 and Cx40, both connexins are lost in the endothelium covering advanced atherosclerotic plaques. In contrast, Cx43 typically has a low expression in the healthy endothelium, is found to increase the formation of atherosclerotic lesions in vivo, and becomes clearly detectable at specific regions of advanced atherosclerotic plaques. Without being bound by theory, it is believed that Cx37 and Cx40 act in an atheroprotective manner, while Cx43 has proatherogenic properties. As such, the agent may preferably be for inhibiting a Cx43 protein, Cx43 hemichannel or Cx43 gap junction.
In preferred embodiments, the agent may be for inhibiting a connexin hemichannel (e.g. Cx43 hemichannel).
In embodiments, any feature of any embodiment of the second aspect may independently be as correspondingly described for any embodiment of any of the other aspects.
In a third aspect, the present invention relates to a pharmaceutical composition comprising an agent according to any embodiment of the first or second aspect or a pharmaceutical composition.
In embodiments, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
In embodiments, any feature of any embodiment of the third aspect may independently be as correspondingly described for any embodiment of any of the other aspects.
In a fourth aspect, the present invention relates to a method of therapy of an ionizing radiation-induced disorder, comprising: (a) inhibiting a connexin protein, connexin hemichannel or connexin gap junction in a subject, and (b) exposing the subject to radiation; wherein step a is performed during and/or after step b.
‘Inhibiting’ is in this context understood to mean ‘bringing or keeping in an inhibited state’. In embodiments, step a may comprise administering an agent according to any embodiment of the first or second aspect or a pharmaceutical composition according to any embodiment of the third aspect. The agent or pharmaceutical composition may bring the connexin protein, hemichannel or gap junction in the inhibited state, where it may remain for some time (e.g. a few hours or days). The inhibition can be prolonged by subsequently administering additional amounts of the agent or pharmaceutical composition. Since ionizing radiation-induced disorders may typically develop in the days, weeks and/or months following the radiation exposure, the connexin protein, connexin hemichannel or connexin gap junction is advantageously inhibited during this time (i.e. after step b). As such, the agent and/or pharmaceutical composition may be administered before, during and/or after the radiation exposure, so that the inhibition may be in effect during and/or after said radiation exposure. In embodiments, administering of the agent and/or pharmaceutical composition may be repeated (e.g. during the days, weeks and/or months following the radiation exposure). This advantageously allows ensuring that inhibition remains into effect during the period where the ionizing radiation-induced disorder may develop.
In embodiments, step b may comprise directly exposing to radiation a cell comprising an inhibited connexin protein, connexin hemichannel or connexin gap junction, or exposing a surrounding cell thereof.
In embodiments, any feature of any embodiment of the fourth aspect may independently be as correspondingly described for any embodiment of any of the other aspects.
In a fifth aspect, the present invention relates to a use of an agent according to any embodiment of the first or second aspect in a method of therapy of an ionizing radiation-induced disorder.
In embodiments, the method of therapy may be a method of therapy according to any embodiment of the fourth aspect.
In embodiments, any feature of any embodiment of the fifth aspect may independently be as correspondingly described for any embodiment of any of the other aspects.
The invention will now be described by a detailed description of several embodiments of the invention. It is clear that other embodiments of the invention can be configured according to the knowledge of the person skilled in the art without departing from the true technical teaching of the invention, the invention being limited only by the terms of the appended claims.
(1): Single and Fractionated Ionizing Radiation Induce Alterations in Endothelial Connexin Expression and Channel Function
We used two human endothelial cell lines: hTERT telomerase immortalized human coronary artery endothelial cells (TICAE) from the European Collection of Authenticated Cell Cultures (ECACC; HCAECs Cat. No: 300-05), and telomerase immortalized human dermal microvascular endothelial cells (TIME) from the American Type Cell Culture (ATTC). TICAE cells are not tumorigenic and they display all major endothelial phenotypic markers, such as, PECAM1, vonWillebrand factor and cadherin-5. In addition, they have a response to radiation exposure similar to their primary counterparts. TIME cells are positive for CD31, capable of taking up Low Density Lipoprotein (LDL), and are karyotypically, morphologically, and phenotypically similar to the primary parent cells (data provided by ATTC).
TICAE and TIME cells were grown in MesoEndo Cell Growth Medium (Sigma-Aldrich Co. LCC, Diegem, Belgium). The passage number that was used in all the experiments (for controls and irradiated conditions) is between passages 26 until passage 32. The cells were kept in a humidified incubator at 37° C. supplemented with 5% CO2 and split every two to three days with a 0.05% trypsin solution supplemented with 0.02% ethylenediaminetetraacetic acid (EDTA) (Life Technologies, Merelbeke, Belgium). Cells were counted via Moxi Z Mini Automated Cell Counter (ORFLO Technologies, Ketchum, Id., USA). Cells were not sub-cultured during the course of the experiments, but medium was changed twice/thrice per week for 7 days and 14 days single irradiation experiments, and for 7 days fractionated irradiation experiment.
Both TICAE and TIME cells were irradiated at 100% confluence with a vertical point source X-ray beam using a Xstrahl RX generator (Camberley, UK; 320 kV, 12 mA, 3.8 mm Al and 1 mm Cu). X-rays doses (0.1, 0.5 and 5 Gy) were delivered to the cells either in one session (‘single irradiation’) or in a fractionated manner with three X-rays doses administered over three consecutive days (0.033 and 1.67 Gy/fraction/day), leading to an accumulative dose of 0.1 and 5 Gy (‘fractionated irradiation’). The dose rate used was 0.5 Gy/min for both single and fractionated exposure. Dosimetry was applied for all the experiments to ensure uniformity of dose and dose rate delivered, following ISO 4037 and ISO-17025 recommendations. Non-irradiated controls for all experiments were treated with the same conditions like irradiated samples, except they are sham-irradiated (0 Gy control).
TICAE and TIME cells were seeded in 6-well plates at a density of 2.5×105 cells/well in five biological replicates. After three/four days, cells reached 100% confluence. The medium was changed before irradiation with 2 ml medium/well for single irradiation experiment, and 3 ml medium/well for fractionated irradiation experiment. Without refreshing the medium, cells were harvested 6, 24, 48 and 72 h post irradiation (p.i.). For the cells harvested 7 and 14 days p.i., the medium was refreshed every two/three days. After harvest, cells were stored in RLT Plus buffer and the total RNA was isolated with the RNeasy® Mini Kit (QIAGEN, Venlo, The Netherlands) according to the manufacturer's instructions. Concentration and quality of RNA were assessed spectrophotometrically using NanoDrop 2000c (Applied Biosystems, Thermofisher Scientific, Waltham, Ma, USA).
The GoScriprt™ Reverse Transcription System (Promega, Leiden, The Netherlands) was used to prepare the complementary DNA (cDNA) by adding 1 μL Random Nucleotide and 1 μL Oligo (dT) primers in 21 μL reactions. After denaturation, a mixture of 8 μL GoScriprt™ 5× Reaction Buffer, 6 μL magnesium chloride (MgCl2), 2 μL PCR Nucleotide Mix, 1 μL Recombinant RNasin® Ribonuclease Inhibitor and 2 μL GoScript™ Reverse Transcriptase was added to each sample.
Two technical replicates for each biological replicate were prepared and quantitative polymerase chain reaction (qPCR) was performed in Fast Optical 96-Well Reaction Plates (Applied Biosystems, Gaasbeek, Belgium) using MESA GREEN qPCR MasterMix Plus for SYBR® Assay Low ROX (Eurogentec, Seraing, Belgium) on a 7500 Fast Real-Time PCR System (Applied Biosystems, Thermofisher Scientific, Waltham, Ma, USA). Amplification occurred at the following cycling conditions: 5 minutes 95° C., 40 cycles of 3 seconds at 95° C., and 45 seconds at 60° C., followed by the generation of a dissociation curve to verify amplification specificity. Reactions contained 12.5 μL 1× Fast SYBR Green Master Mix, 25 mM forward primer and 25 mM reverse primer (sequences selected from literature or qPrimerDepot database (https://primerdepot.nci.nih.gov/)), 20 ng of cDNA template (for all the conditions of all the experiments) and nuclease-free water in a total amount of 25 μL. To evaluate primer efficiency, a standard curve was generated using a two-fold dilution series of a sample over at least five dilution points. In addition, the specificity of the primers was confirmed by performing gel electrophoresis. Primer sequences and efficiencies are shown in Table 1. All measurements were performed in duplicate and the mean of two values from each sample was used in further analyses. The mathematical method of Pfaff1 was used to quantify the gene expression. Housekeeping genes, INPP1 and PGK1 were selected to obtain sample-specific normalization factors.
TICAE and TIME cells were seeded in 6-well plates at a density of 2.5×105 cells/well in four to six biological replicates. After three/four days, cells reached 100% confluence. The medium was changed before irradiation with 2 ml medium/well for single irradiation experiment, and 3 ml medium/well for fractionated irradiation experiment. To extract proteins, 200 μL of RIPA lysis buffer (Roche, Brussels, Belgium), consisting out of 150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1% NP-40/IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, a phosphatase tablet and protease inhibitor tablet (Roche, Brussels, Belgium), was added to 106 cells. Next, cells were homogenized for 30 seconds with a tissue lyser II device (Qiagen, Antwerp, Belgium). The protein concentration was determined with the bicinchoninic acid (BCA) Protein Assay kit (Sigma-Aldrich Co. LLC, Diegem, Belgium). Subsequently, for all the conditions of all the experiments, 10 μg of proteins (except for Cx40 TIME, 20 μg was used) were supplemented with Laemmli buffer (¼ of the total volume) (Bio-Rad, Temse, Belgium), β-mercaptoethanol ( 1/10 of the Laemmli buffer) (Sigma-Aldrich Co. LLC, Diegem, Belgium) and heated at 95° C. for 5 minutes. Electrophoresis was performed at 160 volt and the separated proteins were transferred to a nitrocellulose membrane (Applied Biosystems, Thermofisher Scientific, Waltham, Ma, USA) using the iBlot dry transfer system (Invitrogen™ Thermo Fisher Scientific, Ninove, Belgium). The membranes were blocked for 2-3 h at room temperature using either 5% non-fat dry milk (NFDM) (Bio-Rad, Temse, Belgium) or 5% BSA (Sigma-Aldrich Co. LLC, Diegem, Belgium) (Table 2). Afterwards, membranes were incubated overnight at 4° C. with the appropriate primary antibody (Table 2). After washing, the membrane was incubated for 45 minutes at room temperature with the appropriate horse radish peroxidase (HRP)-conjugated secondary antibodies (Life Technologies, Merelbeke, Belgium) (Table 2). The HRP-immunoreactive bands were visualized with the ECL detection kit (Bio-Rad, Temse, Belgium) and scanned using the Fusion Fx imaging device (Vilber Lourmat, Eberhardzell, Germany). Signals were quantified densitometrically using Bio1D analysis software (Vilber Lourmat, Eberhardzell, Germany) and expressed as relative values (i.e. normalized to the corresponding vinculin signal of the same membrane). Cx37 protein level couldn't be detected with 10-30 μg protein concentration due to the low endogenous level.
The scrape loading and dye transfer assay (SLDT) was used to assess gap junctional function after IR exposure. TICAE and TIME cells were seeded in a 24-well plate at a density of 1×105 cells/well in four to six biological replicates. Three days later, cells reached 100% confluence and the medium was refreshed before irradiation with 1 ml/well for single irradiation experiment and 1.5 ml for fractionated irradiation experiment. At different time points after irradiation (6 and 72 h post single irradiation, or 72 h post fractionated irradiation) the cells were washed 3 times with a scrape loading and dye transfer (SLDT) buffer (137 mM NaCl, 5.36 mM KCl, 0.81 mM MgCl2, 5.55 mM MgCl2.6H2O, 25 mM HEPES, pH 7.4). Then, the cells were incubated with a SLDT solution composed of SLDT buffer and 400 μM 6-carboxyfluorescein (6-CF, 0.376 kDa) (Sigma-Aldrich Co. LCC, Diegem, Belgium) for one minute. A vertical scratch was made in the middle of each well, using a 20G needle (Becton Dickinson, Erembodegem, Belgium). After another one minute incubation, the cells were washed 6 times with HMS supplemented with 25 mM HEPES (Sigma-Aldrich Co. LCC, Diegem, Belgium). Carbenoxolone (Sigma-Aldrich Co. LCC, Diegem, Belgium; 50 μM) was used as a control for blocking gap junctional coupling. After an incubation time of 10 minutes, the cells were visualized with an Eclipse Ti automated inverted wide-field epifluorescence microscope (Nikon, Brussels, Belgium) equipped with a 5×dry objective (Plan Fluor, numerical aperture 0.6) and a Nikon IE2000-E camera controlled by the NIS Elements software. The relative area of 6-CF transfer was calculated using FIJI software. By analyzing the area of the dye diffusion from the first line of cells to adjacent cells, the gap junctional coupling was determined.
Hemichannels are an ATP release pathway and we therefore determined extracellular ATP after irradiation. To that purpose, TICAE and TIME cells were seeded in a 96-well plate at a density of 1×105 cells/well and 0.3×105 cells/well, respectively, in six to eight biological replicates. Three days later, cells reached 100% confluence. At 30 minutes before irradiation, cells were refreshed with 100 μl medium alone or with medium supplemented with 100 μM TAT-Gap19 (Genosphere Biotechnologies, Paris, France) to block the Cx43 hemichannels. For fractionated irradiation, cells were refreshed with 150 μl medium/well. At different time points after irradiation (1, 6 and 72 h), 1:5 ATP assay mix dissolved in ATP mix dilution buffer (Sigma-Aldrich Co. LCC, Diegem, Belgium) was added to each well. Extracellular ATP release was assessed by measuring the luminescence signal received after oxidation of luciferin and ATP to oxyluciferin and AMP using the CLARIOstar® microplate reader (BMG Labtech, Temse, Belgium). Experiments were corrected for baseline ATP signal in medium in the absence or presence of TAT-Gap19.
Hemichannel opening was also investigated by dye uptake studies making use of the hemichannel permeable fluorescent tracer propidium iodide (PI; MW 668.4 Da). In addition, dextran fluorescein 10 kDa dye was used to assess membrane integrity and occurrence of cell death. PI stains cells with open hemichannels, late apoptotic and necrotic cells, while dextran fluorescein only stains late apoptotic and necrotic cells. Therefore, PI-positive and dextran fluorescein-negative cells are a measure for hemichannel opening while dextran fluorescein-positive cells are a measure for dead cells.
TICAE and TIME cells were seeded in a 24-well plate at a density of 1.25×105 and 1.5×105 cells/well, respectively, in six biological replicates. Three days later, cells reached 100% confluence. Thirty minutes before irradiation, cells were refreshed with 1 ml medium alone or with medium supplemented with 100 μM TAT-Gap19 (Genosphere Biotechnologies, Paris, France). For fractionated irradiation, cells were refreshed with 1.5 ml medium/well. At different time points after irradiation (1, 6 and 72 h), cells were washed twice with HMS supplemented with 25 mM HEPES (Sigma-Aldrich Co. LCC, Diegem, Belgium) (HBSS-HEPES). Afterwards, the cells were incubated with 1 mM PI and 200 μM dextran fluorescein (10 kDa) (Life Technologies, Merelbeke, Belgium), dissolved in HBSS-HEPES for 5 minutes followed by 5 times washing with MSS-HEPES. Finally, the fluorescence was measured using an IncuCyte ZOOM® system (Essen BioScience, Ann Arbor, Mich., USA) by using different channels (TRITC, FITC and phase contrast) and a 10× objective Fluorescence signal was normalized to cell number.
In order to have an overview of the results, principal component analysis (PCA) was performed for Cx40 and Cx43 gene expression and protein level (assessed by RT-qPCR and western blot) for both TICAE and TIME cells after single irradiation over the 6 h to 14 d p. i. time period. As the same sample was not used for both qPCR and western blot analysis, and the number of replicates were varying from 4-6 replicates, the means of the various replicates for each time point/radiation dose were calculated and PCA was performed using the prcomp command in R software (v 3.4.3). Both first and second components were plotted in the horizontal and vertical axes, respectively. For each time point and each radiation dose, the gene expression/protein level profile was averaged and analyzed using two-dimension PCA.
All experiments were analyzed with a nonparametric Mann-Whitney T-test. The results were considered statistically significant when P<0.05. Data are presented as mean±standard error of the mean. Statistical analysis was done with GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, Calif. 92037 USA). Occasional exclusion of outlier data points were done using Grubbs' test.
a. Single Irradiation
TICAE and TIME cells were exposed to different single doses of X-rays (0.1, 0.5 and 5 Gy) and assessed for changes in Cx gene expression at different time points (6 h, 24 h, 48 h, 72 h, 7 d and 14 d p.i.).
In TICAE cells, a radiation-induced downregulation in Cx37 gene expression was observed starting from 24 h p.i., which persisted up to 14 d p.i. and were mainly significant for the 0.5 Gy and 5 Gy doses. For 0.1 Gy exposures, Cx37 gene expression was significantly upregulated at an early time point (6 h p.i.), while downregulated at a late time point (7 d p.i.) (
Gene expression of Cx40 was downregulated in TICAE cells starting from 6 h and persistent up to 7 d p.i., mainly significant at 5 Gy (
Different from Cx37 and Cx40, irradiation mainly resulted in an upregulation of Cx43 gene expression for the 0.5 and 5 Gy doses. In TICAE cells, 5 Gy induced significant upregulation of gene expression at 6 h and 48 h p.i., which persisted up to 7 d p.i.. For the 0.5 Gy dose, upregulation normalized more rapidly (
a. Fractionated Irradiation
An early and late time point (24 h and 7 d p.i.) were selected to evaluate the effect of fractionated irradiation on Cx gene expression, and to compare it to single exposure effect (by comparing the relative gene expression (fold change) between single and fractionated exposure to their respective normalized controls).
For Cx37, fractionated irradiation of TICAE cells resulted in a downregulation of gene expression, which was significant for 5 Gy at both time points and for 0.1 Gy only at the 7 d time point, like single dose irradiation (
For Cx40, fractionated irradiation of TICAE cells resulted in significant downregulation of gene expression for the 5 Gy dose at 24 h, like single irradiation, but not at 7 d, unlike single irradiation, resulting in significant differences for the two radiation regimens at 5 Gy for the 7 d time point (
For Cx43, fractionated irradiation of TICAE cells induced significant upregulation of gene expression at the 24 h time point and things recovered at the 7 d time point, but there were no significant differences for the two radiation regimens (
a. Single Irradiation
TICAE and TIME cells were exposed to different single doses of X-rays (0.1, 0.5 and 5 Gy) and assessed for changes in Cx protein levels at different time points (6 h, 24 h, 48 h, 72 h, 7 d and 14 d p.i.). Expression of Cx37 protein could not be detected with the 10-30 μg protein concentration used, indicating low endogenous levels.
A radiation-induced acute and persistent decrease in Cx40 protein level was observed in a dose-dependent manner in both TICAE and TIME cells. In TICAE cells
We found a radiation-induced acute and persistent increase in Cx43 protein level that was dose-dependent for both TICAE and TIME cells. For the 5 Gy dose, the increase was significant for all time points except for 14 d p.i.; for the 0.5 Gy dose, all time points except 48 h were significant; for 0.1 Gy, a significant increase was apparent from 72 h on, which remained high up to 14 d p.i. (
In addition, a radiation-induced increase in the phosphorylated (p) and hyperphosphorylated (pp) forms of Cx43 were observed in TICAE cells at 24 h, 48 h, 7 d and 14 d p.i. (mainly significant at 0.5 Gy and 5 Gy) (
b. Fractionated Irradiation
An early and late time point (24 h and 7 d p.i.) were selected to evaluate the effect of fractionated irradiation on Cx protein expression, and to compare it to single exposure effect.
For Cx40, fractionated irradiation of TICAE cells induced a significant decrease in the protein level only for the 5 Gy dose at the 24 h and 7 d time points, but the effects were less pronounced compared to single irradiation at 7 d time points (
For Cx43, fractionated irradiation of TICAE cells induced an increase in the protein level, which was most clear at the 24 h time point (significant for both 0.1 and 5 Gy doses) and less prominent at the 7 d time point (significant for 5 Gy only) (
a. Single Irradiation
After exposure of TICAE and TIME cells to a single dose of 0.1 or 5 Gy, SLDT assays were performed at 6 h and 72 h p.i. At 6 h p.i., a significant increase in 6-CF diffusion area was observed for the 5 Gy dose in TICAE cells compared to control non-irradiated cells (
b. Fractionated Irradiation
The 72 h p.i. time point was selected to evaluate the effect of fractionated irradiation on dye spread (fractionated irradiation as applied in the preceding experiments), and to compare it to single exposure effect. For TICAE and TIME cells, only the 5 Gy dose resulted in significantly increased dye spread (
We first assessed hemichannel opening by determining ATP release in response to 0.1 Gy and 5 Gy irradiation at 1 h, 6 h and 72 h p.i. and tested the effect of hemichannel blockade with TAT-Gap19 which blocks hemichannels composed of Cx43 while it does not inhibit gap junctions.
a. Single Irradiation
In TIME cells, the effects were most strong and both 0.1 and 5 Gy doses triggered significant ATP release at all time points (1, 6 and 72 h) (
b. Fractionated Irradiation
The 72 h p.i. time point was selected to evaluate the effect of fractionated irradiation on ATP release, and to compare it to single exposure effect (
To further assess hemichannel opening, the previous experiments were complemented with dye uptake assays using propidium iodide (PI) and 10 kDa dextran fluorescein as reporter dyes. As an additional control, we also verified the effect of Cx43 hemichannel blockade with TAT-Gap19.
a. Single Irradiation
A radiation-induced increase in dye uptake was mainly significant for the 5 Gy dose at 1 h, 6 h and 72 h p.i. in both TICAE and TIME cells; in TIME cells, the lower 0.1 Gy dose also gave significant dye uptake (
b. Fractionated Irradiation
The 72 h time point was selected to evaluate the effect of fractionated irradiation on PI dye uptake, and to compare it to single exposure effect. Fractionated irradiation induced an increase in dye uptake in TICAE and TIME cells exposed to 5 Gy but here TAT-Gap19 had no effect (
In order to have a concise view on the major effects observed, we performed principal component analysis (PCA) for Cx40 and Cx43 gene expression and protein level in both TICAE and TIME cells after single irradiation over the 6 h to 14 d p.i. time period (
Growing epidemiological data suggest that endothelial cell irradiation induces atherosclerosis. However, the underlying mechanisms are not fully understood. Although connexins were reported to be sensitive to IR and to play a role in atherosclerosis development, their role in radiation-induced atherosclerosis has been poorly explored. Here, we aimed to investigate changes in connexin expression and channel function in response to IR, as a putative mechanism leading to radiation-induced endothelial cell dysfunction, an early event in the atherosclerotic process. We report that single and fractionated X-ray irradiation of coronary artery and microvascular endothelial cells, at doses that can be received after serial diagnostic procedures (0.1 Gy) or as out-of-field exposure after radiotherapy (5 Gy), significantly alters endothelial connexin gene expression, protein levels, gap junctional dye coupling and hemichannel function. Below we discuss these findings in more detail.
We demonstrate changes in Cx37 gene level, consisting of an early (6 h) upregulation at 0.1 Gy followed by a dose-dependent downregulation in TICAE cells and fluctuating responses in TIME cells. These alterations indicate that Cx37 modulation in response to IR is cell line specific, possibly related to distinct endothelial properties at different sites of the vascular tree. For Cx40, gene expression was up at the early time point for the 0.1 Gy dose in the two cell types, as observed for Cx37. Higher doses mainly gave downregulation in TICAE cells and showed more variable responses in TIME cells. Interestingly, the early transient upregulation at 0.1 Gy for both Cx37 and Cx40 genes, observed in both cell types, may reflect possible early protective effects. Protective effects after low dose ionizing irradiation in endothelial cells, such as diminished leukocyte adhesion and enhanced antioxidative defence were reported before. In contrast to the sometimes fluctuating gene expression responses, changes in protein levels of Cx40 were coherent, demonstrating dose-dependent downregulation, significant from low dose (0.1 Gy) at different time points in TICAE and TIME cells. For Cx43, gene expression and protein levels grossly corresponded and demonstrated a dose-dependent elevation at different time points in TICAE and TIME cells. We furthermore found radiation-induced elevation of phosphorylated and hyperphosphorylated Cx43 forms for both cell types. Interestingly, a previous study showed that endothelial Cxs have a distinct temporal expression pattern over time in non-irradiated conditions. In summary, as indicated in PCA (
As radiotherapy is delivered to the tumour in multiple radiation fractions, assessing the effect of fractionated irradiation on vascular endothelial cells is of clinical importance. As indicated in PCA (
In addition to alterations at the gene and protein level, we also observed functional changes at the level of both gap junctions and hemichannels. Overall, it was clear that irradiation increased gap junctional communication as assessed by dye coupling, which was most obvious at 72 h post single and fractionated irradiation in both TICAE and TIME cells. Taken together, the prominent presence of Cx43 in vascular endothelial cells of the major arteries, combined with the variable observations for Cx37 gene alterations and the decreased level of Cx40 protein, the observed increase in gap junctional coupling is likely caused by the increased Cx43 expression, possibly in combination with the increase in phosphorylated forms that act to enhance gap junctional communication. At the level of hemichannels, we used ATP release and propidium iodide dye uptake assays to estimate functional alterations. To further increase the robustness of the responses, we used TAT-Gap19, a Cx43 hemichannel inhibitor not inhibiting gap junction channels, to determine whether the responses were Cx43 hemichannel-related.
In conclusion, to the best of our knowledge, we show for the first time that exposure of coronary artery and microvascular endothelial cells to single or fractionated X-rays, induced an acute and persistent dose-dependent decrease of atheroprotective Cx40 and increase of the proatherogenic Cx43 gene and protein levels. In addition, such radiation exposures increased gap junctional communication and induced acute and long-lived hemichannel opening, the latter considered as a pathological condition. We believe that radiation-induced increased endothelial gap junctional coupling and hemichannel function leads to endothelial dysfunction, which is an early marker for atherosclerosis.
Two human endothelial cell lines; Telomerase Immortalized human Coronary Artery Endothelial cells (TICAE) from the European Collection of Authenticated Cell Cultures (ECACC), and Telomerase Immortalized human Microvascular Endothelial cells (TIME) from the American Type Cell Culture (ATTC), were grown in MesoEndo Cell Growth Medium (Sigma-Aldrich Co. LCC, Diegem, Belgium) in a humidified incubator at 37° C. supplemented with 5% CO2. Cells were split every three days with 0.05% trypsin supplemented with 0.02% ethylenediaminetetraacetic acid (EDTA). The passage number 28 until passage 36 was used in all the experiments. Moxi Z Mini Automated Cell Counter (ORFLO Technologies, Ketchum, Id., USA) was used to count the cells. Cells were not passaged after irradiation for all experiments.
TICAE and TIME cells were irradiated at 100% confluence with 0.1 Gy and 5 Gy single X-rays doses at a dose rate of 0.5 Gy/minute with a vertical, point source X-ray beam using a Xstrahl RX generator (320 kV, 12 mA, 3.8 mm Al and 1 mm Cu) (Camberley, UK).
TICAE and TIME cells were seeded in a 6-well plate at a density of 250000 cells/well. Three days later, cells reached 100% confluence. At 30 minutes before X-ray exposure (0.1 and 5 Gy), cells were washed with PBS to remove traces of the original medium. Afterwards, HMS supplemented with 25 mM HEPES (Sigma-Aldrich Co. LCC, Diegem, Belgium) and 10 μmol/L of the CM-H2DCFDA dye (Sigma-Aldrich Co. LCC, Diegem, Belgium) was added to the cells, and 100 μM TAT-Gap19 (Genosphere Biotechnologies, Paris, France) was added to block the Cx43 hemichannels. After irradiation, cells were washed with PBS and a 0.05% trypsin solution supplemented with 0.02% EDTA was used to detach the cells, followed by a 5 minute incubation time (37° C., 5% CO2). After trypsinization, the cells were transferred into a 1.5 mL tube and centrifuged for 0 minutes at 200 RCF. The supernatant was discard and the pellet was re-suspended in MSS without Ca2+ and Mg2+(Sigma-Aldrich Co. LCC, Diegem, Belgium). Finally, 1 μg/mL PI was added to each sample to exclude the dead cells. A positive control, 20 μmol/L tert-butyl hydroxyperoxide (tBHP), was added to the cells and incubated for 15 min. Intracellular ROS was assessed by analyzing the fluorescent signals using BD Accuri™ c6 Flow Cytometry (BD Biosciences, San Jose, Calif. USA). At least 10 000 events were measured. Before analysis, a color compensation for the CM-H2DCFDA and PI staining was performed, by using single color controls (cells treated with CM-H2DCFDA or PI, and untreated cells) and adjusting the fluorescent signals in the FL1 and FL3 channels. Gating was adjusted based on CM-H2DCFDA positive and PI negative condition in control non-irradiated cells.
In order to further assess intracellular ROS production, IncuCyte live cell imaging was used to have fast imaging in large number of replicates over multiple time points. TICAE and TIME cells were seeded in 96-well plate in 16 replicates at a density of 10000 cells/well. Three days later, cells reached 100% confluence. At 30 minutes before irradiation, a fresh MesoEndo Cell Growth Medium without phenol red (Sigma-Aldrich Co. LCC, Diegem, Belgium) supplemented with 10 μmol/L of the CM-H2DCFDA dye (Sigma-Aldrich Co. LCC, Diegem, Belgium) was added to the cells, with or without 100 μM TAT-Gap19 (Genosphere Biotechnologies, Paris, France). Fluorescence signals were measured at 45 min, 2 h and 3 h after irradiation (CM-H2DCFDA dye became saturated due to photoactivaton, and leaked outside the cells after this time) using the IncuCyte ZOOM® system (Essen BioScience, Ann Arbor, Mich., USA), 10× objective and FITC filter. Phase contrast imaging was performed in order to count the cells. A positive control of 10 μmol/L tert-butyl hydroxyperoxide (tBHP), was added to the cells directly before imaging. Images were analysed making use of the software package provided by the manufacturer; we used a training set of images from different doses to define the image processing procedure. The so called Top-Hat background subtraction method was applied by measuring the radius of the fluorescence object (30 μm), and adjust a threshold of 1.5 (above the local background fluorescent intensity level), as described in IncuCyte™ Background Fluorescence Technical Note. These process definitions were applied for all conditions in TICAE and TIME cells.
TICAE and TIME cells were seeded in 96 well plates at a density of 10000 cells/well in 8 biological replicates. After three days, cells were at 100% confluence. At 30 minutes before X-ray exposure, cells were refreshed with 200 μl medium supplemented with Caspase 3/7 reagent (1:1000 dilution) and Annexin V reagent (1:200 dilution) (Essen Bioscience, United Kingdom) with or without 100 μM TAT-Gap19 (Genosphere Biotechnologies, Paris, France). Fluorescence signals were measured from 4 h until 100 h after irradiation by imaging every 2 hours using the IncuCyte ZOOM® system (Essen BioScience, Ann Arbor, Mich., USA). Different channels (TRITC, FITC and phase contrast) and a 10× objective were used. Spectral unmixing set as 8% of red removed from green was applied. The IncuCyte software's processing definition was set to recognize red (Annexin V) and green (Caspase 3/7) stained cells, making use of the Top-Hat background subtraction method. Fluorescence signal was normalized to cell count.
Dextran fluorescein, staining late apoptotic and necrotic cells, was used to validate apoptosis in TIME cells after irradiation. Cells were seeded in a 24-well plate at a density of 1.5×105 cells/well in 6 biological replicates. Three days later, cells reached 100% confluence. Before X-ray exposure with 30 minutes, cells were refreshed with medium with or without 100 μM TAT-Gap19 (Genosphere Biotechnologies, Paris, France). At 6 h and 72 h after irradiation, cells were washed twice with HMS supplemented with 25 mM HEPES (Sigma-Aldrich Co. LCC, Diegem, Belgium) (HBSS-HEPES). Afterwards, the cells were incubated with 200 μM dextran fluorescein (10 kDa) (Life Technologies, Merelbeke, Belgium), dissolved in HBSS-HEPES. After six minutes, the staining was removed by washing six times with HBSS-HEPES. Finally, the fluorescence was measured using the IncuCyte ZOOM® system (Essen BioScience, Ann Arbor, Mich., USA) by using FITC channel and phase contrast to count the cells using a ×10 objective. The fluorescence signal was normalized to cell count.
TICAE and TIME cells were seeded in a 6-well plate at a density of 2.5×105 cells/well in 5 to 6 biological replicates. Two to three days later, cells reached 100% confluence. At 30 minutes before X-ray exposure, cells were refreshed with medium with or without 100 μM TAT-Gap19 (Genosphere Biotechnologies, Paris, France). At 24 h, 48 h, 72 h and 7 d after irradiation, the supernatant was collected. Medium was changed only for the 7 d time point experiment at the fourth day with fresh medium alone or with medium supplemented with 100 μM TAT-Gap19. For the simultaneous detection of multiple cytokines in the supernatants, the Magnetic Luminex® Assay (R&D systems, Minneapolis, Canada) was used following manufacturer's instructions. Briefly, supernatants, standards and microparticles were incubated into a 96-well plate which was pre-coated with cytokine-specific antibodies. The immobilized antibodies were able to bind the cytokines of interest after 2 h incubation, then the plate was washed and incubation with a biotinylated antibody cocktail specific to the cytokines of interest was performed for 1 h. A second wash was performed to remove the unbound biotinylated antibodies. Further, a streptavidin-phycoerythrin conjugate was added to each well to bind to the biotinylated antibodies. After a final wash, the microparticles were resuspended in buffer and read using the Luminex® MAGPIX Analyzer (R&D systems, Minneapolis, Canada).
In order to normalize to cell number, DAPI staining was performed for the 48 h after irradiation time point. Briefly, cells were washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. Afterwards, the cells were washed with PBS and stained with 1 μg/mL 4′,6-Diamidine-2′-phenylindole (DAPI) dissolved in 1×TBST, 0.005 g/v % TSA blocking powder (PerkinElmer, FP1012) (TNB). After one hour, cells were washed with PBS and DAPI signals were visualized with the Nikon Eclipse Ti automated inverted wide-field epifluorescence microscope equipped with a 5× magnification (Plan Fluor, numerical aperture 0.6) dry objective and a Nikon IE2000-E camera controlled by the MS Elements software. The intensity of the DAPI signals was determined with the FIJI software. Cell count for 24 h after irradiation experiment was performed by Moxi Z Mini Automated Cell Counter (ORFLO Technologies, Ketchum, Id., USA) after trypsinization. For the 72 h and 7 d post-irradiation cell counts, we used IncuCyte ZOOM™ phase contrast imaging based on 49 images taken per well with the 10× objective.
TICAE and TIME cells were seeded in 96 well plates at a density of 10000 cells/well in 16 replicates. Three days after, cells were at 100% confluent. At 30 minutes before X-ray exposure, the cells were refreshed with 150 μl medium alone or with medium supplemented with 100 μM TAT-Gap19 (Genosphere Biotechnologies, Paris, France). For 7 d and 9 d post irradiation experiments, the medium was refreshed once, while for 14 d post irradiation experiment the medium was refreshed twice with 200 μl medium alone or with medium supplemented with 100 μM TAT-Gap19. At 7, 9 and 14 days post irradiation, cell number was determined using an Incucyte® ZOOM life cell analysis system and related software (Essen Bioscience, Hertfordshire, United Kingdom). Afterwards, the senescence associated β-galactosidase activity in the cells was determined using the chlorophenol red β-D-galactopyranoside (CPRG) assay as described previously. The cells were washed with PBS and lysed using M-PER™ buffer (Thermo Fisher Scientific, Asse, Belgium). Subsequently, 1×CPRG substrate (2 mM Chloropenol Red β-D-galactopyranoside in CPRG assay buffer containing 50 mM KPO4, 1 mM MgCl2, pH 6) (Sigma-Aldrich, Overijse, Belgium) was added to each well and the plates incubated for 18 h at 37° C. without CO2. A CLARIOstar® microplate reader (BMG Labtech, Temse, Belgium) was used to measure the absorbance at 570 nm.
To detect DNA double strand breaks after IR, TICAE and TIME cells were seeded in Nunc™ Lab-Tek™ Chamber Slide (Thermo Fisher Scientific, Asse, Belgium) in 8 replicates, at seeding density of 50 000 cells/well. Two days later, cells reached 100% confluence. At 30 min before IR, a fresh medium was added to the cells with or without 100 μM TAT-Gap19. At 1 h post irradiation, cells were fixed with 2% PFA (Sigma-Aldrich Co. LCC, Diegem, Belgium) and permeabilized with 0.25% Triton X-100 (Sigma-Aldrich Co. LCC, Diegem, Belgium) in PBS. Cells were blocked for 1 h in 1% normal goat serum (Thermo Fisher Scientific, Asse, Belgium) in Tris-NaCl (Perkin Elmer, Brussels, Belgium). Thereafter, staining with 1/300 primary anti-gamma H2AX antibody (Merck-Millipore #05-636) and 1/1000 anti-TP53BP1 antibody (Novus Biologicals #NB100-304) was performed for 1 h at 37° C. After washing 3 times with PBS, secondary Alexa Fluor 488 and 568 antibodies (Life Technologies, Merelbeke, Belgium) were applied for 1 h at 37° C. Finally, the slides were mounted using ProLong Diamond Antifade Mountant with DAPI (Life Technologies, Merelbeke, Belgium), and cells were visualized with an Eclipse Ti automated inverted wide-field epifluorescence microscope (Nikon, Brussels, Belgium) equipped with a 20×Plan Fluor objective (NA 0.6) and an Andor Ixon EMCCD camera, controlled by the MS Elements software. A z-stack of 9 planes axially separated by 1 μm was applied, and 16 fields were captured for each replicate. Analysis were performed with FIJI software using the Cellblocks toolbox.
Nonparametric two-tailed Mann-Whitney T-test was performed for the analysis of all the experiments, except for dead cell live cell imaging experiment where two-way ANOVA analysis followed by Turky test was used. Statistical significance was considered when P<0.05. Data are presented as mean±standard error of the mean. GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, Calif. 92037 USA) was used in all the analysis and occasional exclusion of outlier data points were performed using Grubbs' test.
Intracellular ROS production was measured in TICAE and TIME cells in response to exposure to 0.1 Gy and 5 Gy X-rays, making use of flow cytometric measurement of CM-H2DCFDA dye fluorescence. A dose-dependent ROS increase was observed at the 45 min time point in TICAE and TIME cells (
In order to obtain more detailed temporal information on ROS production, we used IncuCyte live cell imaging of CM-H2DCFDA fluoresecence in TICAE and TIME cells at 45 min, 2 h and 3 h after IR exposure. In TICAE and TIME cells, a radiation-induced dose-dependent increase in intracellular ROS production was observed from 45 min until 3 h post irradiation (p.i.) (significant for 0.1 and 5 Gy), with the highest response at 45 min p.i. (
In order to investigate cell death after IR exposure, Annexin V (early and late apoptotic cells) and Caspase 3/7 activity (late apoptotic cells) were assessed in TICAE and TIME cells from 4 h until 100 h after IR using IncuCyte live cell imaging. We furthermore tested the effect of hemichannel inhibition with TAT-Gap19.
In TICAE cells, a significant increase in Caspase 3/7 activity and Annexin V was observed for the 5 Gy dose starting from 4 h and persistent until 100 h p.i., the last point of the recording (
In TIME cells, there was no significant change in Caspase 3/7 activity after 0.1 Gy and 5 Gy of IR until 100 h p.i. (
To further validate cell death in TIME cells, 10 kDa dextran fluorescein dye, which is known to enter and stain cells during necrosis or late apoptosis, was assessed at 6 h and 72 h p.i. A radiation-induced increase in dextran fluorescein was observed for 5 Gy at 6 h p.i. and for both 5 and 0.1 Gy doses at 72 h p.i. (
Different atherosclerosis inflammatory markers, selected based on a survey of available literature, were assessed in TICAE and TIME cells after 0.1 Gy and 5 Gy of IR exposure at 24 h, 48 h, 72 h and 7 d p.i. We subsequently tested whether hemichannel inhibition with TAT-Gap19 affected these responses. The various inflammatory markers used are summarized in
In general, IR exposure at a 5 Gy dose induced an increase in the majority of the markers (IL-6, MCP-1, PECAM-1, IL-1B, TNF-α, CRP, VCAM-1, E-selectin, Endothelin-1, IL-8 and PAI-1) in both TICAE and TIME cells. TAT-Gap19 displayed variable effects, in some conditions decreasing while in others increasing the responses, especially in TICAE cells (
In TIME cells, a radiation-induced significant increase in IL-6 at 5 Gy was observed at 24 h, 48 h and 7 d p.i., and TAT-Gap19 significantly reduced these responses (
I. Inhibiting hemichannels protects from radiation-induced premature endothelial senescence
In order to assess premature senescence in TICAE and TIME cells after 0.1 Gy and 5 Gy irradiation and to evaluate the effect of blocking Cx43 hemichannels, senescence-associated β-galactosidase (SA β-gal) activity was measured at 7, 9 and 14 d after exposure.
In TICAE cells, a radiation-induced increase in SA β-gal activity was observed for 5 Gy at 7 and 9 d p.i.. By contrast, at the 0.1 Gy 7 d p.i. time point, SA β-gal activity was significantly decreased (
In order to further assess premature senescence, levels of the Insulin-like Growth Factor-binding Protein-7 (IGFBP-7) and GDF15 growth differentiation factor 15 (GDF-15), known to be involved in senescence, were assessed at 7 d after IR exposure using multiplex-based assays. A radiation-induced increase in IGFBP-7 was observed at 5 Gy for TICAE and TIME cells, but this response was not inhibited by TAT-Gap19. By contrast, 0.1 Gy did not significantly increase IGFBP-7 at 7 d p.i. but TAT-Gap19 acted in a significantly inhibitory way in this condition (
DNA damage was assessed by immunocytochemical staining for gamma H2AX and TP53BP1, DNA double strand break markers, in TICAE and TIME cells after 1 h of X-ray exposure (0.1 Gy and 5 Gy). We furthermore tested the effect of hemichannel inhibition with TAT-Gap19.
In TICAE and TIME cells, radiation induced a significant dose-dependent increase in gamma H2AX and TP53BP1 foci at the 5 Gy dose (
Patients treated with radiotherapy have an increased risk of cardiovascular disease, but the underlying pathophysiology is complex and not fully understood. Here, we aimed to investigate the role of Cx43-based hemichannels in radiation-induced endothelial cell damage, an early marker of atherosclerosis, making use of the peptide inhibitor TAT-Gap19. We found that this peptide significantly reduced oxidative stress, cell death, key inflammatory cytokines and premature cell senescence induced by X-ray exposure of endothelial cell lines derived from coronary artery and microvascular endothelial cells. Below we discuss these findings in more detail.
A predominant effect of IR exposure is ROS production and oxidative stress. Accordingly, in TICAE (coronary artery-derived) and TIME cells (microvascular endothelial cells TIME), we found a dose-dependent increase in oxidative stress after 0.1 Gy and 5 Gy of X-ray exposure as measured by CM-H2DCFDA-based flow cytometric and live cell imaging approaches. The highest oxidative stress response was observed at 45 min p.i. in both cell types, followed by a decline to the 2 and 3 h time points; the latter were however still significantly above non-irradiated controls. The decline at 2-3 h may be linked to antioxidant defence reactions of enzymes such as superoxide dismutases (SOD), glutathione, glutathione peroxidases, catalase and others. A similar time line has been observed in primary microvascular endothelial cells exposed to gamma-rays. Interestingly, we found that blocking Cx43 hemichannels with TAT-Gap19 significantly reduced ROS production in both cell types at 45 min p.i. (
It is well known that oxidative stress is associated with the activation of various cascades including the DNA damage response, apoptosis and inflammatory pathways, thereby amplifying endothelial dysfunction. We observed radiation-induced DNA damage in the two cell types at 1 h p.i., as evidenced from gamma-H2AX and TP53BP1 foci analysis. These findings are consistent with previous studies where a dose-dependent increase in DNA damage was observed in EA.hy926 endothelial hybrid cells, in umbilical vein endothelial cells, as well as in coronary artery endothelial cells in response to X-ray doses in the range of 0.05 to 2 Gy, and in microvascular endothelial cells after 3 and 10 Gy of gamma-rays. Our findings showed that TAT-Gap19 did not alter this DNA damage response in the irradiated TICAE and TIME cells.
We found that cell death in the two cell types mainly occurred after 5 Gy irradiation, with TICAE cells responding with Annexin V and Caspase 3/7 elevation while TIME cells responded with Annexin V elevation and membrane leakage as indicated by cellular dextran fluorescein positivity. The absence of Caspase 3/7 elevation in TIME cells confirms the findings in primary human microvascular endothelial cells exposed to X-rays in the 2 to 12 Gy dose range. Overall, the cell death observed in our study is in line with previous findings in umbilical vein endothelial cells and microvascular endothelial cells. Interestingly, we show that TAT-Gap19 significantly reduced cell death in irradiated TICAE and TIME cells. Cx43 hemichannels are known to mediate cell death in various model systems as well as in cardiomyocytes exposed to hypoxia-reoxygenation or ischemia-reperfusion, by facilitating the passage of soluble factors and molecules such as ATP, ROS and Ca2+. It was reported that IR induces hemichannel-related ATP release which may cause intracellular ATP depletion, thereby activating cell death process through necrosis or apoptosis. Hemichannel opening has furthermore been suggested to facilitate ROS entry into the cells eventually leading to cell death.
Inflammation plays a key role in atherosclerosis development and progression. In this study, we showed that radiation induced an increase in atherogenic inflammatory markers (IL-6, MCP-1, PECAM-1, IL-1B, TNF-α, CRP, VCAM-1, E-selectin, endothelin-1, IL-8 and PAI-1) mainly at 5 Gy, in both TICAE and TIME cells. Observations in various endothelial cells confirm an elevation of these inflammatory markers mainly at higher irradiation doses (>2 Gy). We found that TAT-Gap19 significantly reduced the elevated IL-1B, IL-8, VCAM-1, MCP-1 and endothelin-1 levels in the two cell lines, at late time points (72 h and 7 d), while it also had early (24 h) inhibitory effects in TIME cells. In addition, TAT-Gap19 displayed early (24 h) inhibition of TNF-α, E-Selectin, PECAM-1, CRP and ICAM-1 but only in TIME cells, indicating that Cx43 hemichannel involvement in the inflammatory response is time and cell type dependent. All cytokines listed are known to be strongly involved in the pathogenesis of radiation-induced atherosclerosis. The cytokine response is triggered by IR/oxidative stress-induced NF-κB signaling and results in endothelial cell activation with subsequent expression of adhesion molecules. TNF-α was shown to induce smooth muscle cell proliferation and to increase monocyte adherence to endothelial cells by inducing the expression of cell adhesion molecules. Expression of adhesion molecules, such as VCAM-1, ICAM-1, PECAM-1 and E-selectin, on the vascular wall is known to initiate the recruitment of macrophages and leukocyte from the vasculature, that acts together with MCP-1 and IL-8 to induce infiltration of macrophages into the subendothelial cell layer, leading to the formation of atherosclerotic lesions. IL-6 has also been shown to be responsible for propagating downstream inflammatory responses, which involve lipoprotein oxidation by phospholipases, recruitment of other pro-inflammatory cytokines and the release of prothrombotic mediators, that contribute to atherosclerotic plaque development and plaque destabilisation. Moreover, an increased production of the potent vasoconstrictor peptide Endothelin-1 was linked to endothelial cell dysfunction, as it may decrease endothelial nitric oxide synthase (eNOS) expression, thereby reducing nitric oxide (NO) vasodilatory signaling, impairing the regulation of vascular tone. Endothelin-1 was also reported to activate macrophages, thereby supplementing the pro-inflammatory and chemotactic scene with TNF-α, IL-6, IL-8 and others, which are involved in the pathogenesis of atherosclerosis. Importantly, it is thought that Cx43 hemichannel opening may continue and propagate the inflammatory scene. In addition, upregulated Cx43 expression often correlates with increased inflammatory responses, while reduced Cx43 expression inhibits inflammation. TAT-Gap19 has been demonstrated to significantly decrease IL-1B and TNF-α in non-alcoholic fatty liver mouse model. Peptide5, another mimetic peptide-based hemichannel blocker was reported to reduce TNF-α and IL-1B in rat model of spinal cord injury. This peptide also reduced inflammation in a rat model of light-induced retinal damage, as assessed by glial fibrillary acidic protein (GFAP) and leukocyte common antigen (CD45) immunohistochemistry. A possible mechanism by which Cx43 hemichannels contribute to inflammation is through their regulatory effect on high-mobility group box 1 (HMGB1), which serve as a damage-associated molecular pattern molecule (DAMP). HMGB1, released by apoptotic cells, induces IL6, IL-8 and MCP-1 secretion and increases the expression of ICAM-1 and VCAM-1 in endothelial cells. Furthermore, by releasing ATP, Cx43 hemichannels enhance inflammation through downstream activation of the NLRP3 inflammasome. Cx43 hemihannels may thus act to amplify and perpetuate an initial inflammatory condition. Interestingly, IR induces a rapid and persisting increase in Cx43 gene and protein expression in TICAE and TIME cells, thereby creating pro-inflammatory substrate.
In contrast to the inflammatory mitigating effect of TAT-Gap19 on irradiated endothelial cells, the peptide transiently increased some other inflammatory markers at various time points (
Interestingly, inflammation has been reported to contribute to cellular senescence. Premature cell senescence is known to contribute to endothelial dysfunction by stimulation a complex pro-inflammatory response, including the release of adhesion molecules such as IL-6, IL-8. MCP-1 and IGFBP, and it is known to trigger the initiation of cell death by reducing cell repair ability. Furthermore, endothelial senescent cells are known to increase levels of ROS partly due to downregulation of eNOS leading to mitochondria dysfunction. Our experiments showed an increase in SA-β gal activity in TICAE and TIME cells mainly at 7 and 9 d p.i. This increase in SA-β gal activity was persistent until 14 d p.i. only at 0.1 Gy. For 5 Gy, an unexpected decrease in SA-β gal activity was observed, which may be caused by the frequent medium change for this time point, resulting in washout of senescent cells and replacement by proliferating cells at the high dose. Premature senescence in TICAE and TIME cells was also apparent from the increase in IGFBP-7 (at 5 Gy) and GDF-15 (at 0.1 and 5 Gy) 7 d p.i. GDF-15 is suggested to contribute to premature cell senescence induced by irradiation via the ROS-mediated p16 pathway, while IGFBP-7 is suggested to induce senescence via inhibition of BRAF-MEK-ERK signalling. Additionally, GDF-15 was reported to be involved in the pathogenesis of atherosclerosis by regulating IL-6 and macrophage chemotaxis. Our results are in line with previous studies, where cellular senescence was observed after low and high doses of IR exposure in different types of endothelial cells, including human coronary artery. Interestingly, TAT-Gap19 significantly suppressed the radiation-induced increases in SA-0 gal activity and GDF-15 levels in TICAE and TIME cells suggesting a role for Cx43 hemichannels. Senescence can be communicated to neighbouring cells in a paracrine manner involving secretion of senescence-associated secretory phenotype (SASP) and inflammasome activation. Presumably, Cx43 hemichannels may perhaps facilitate paracrine senescence communication between cells via its effects on pro-inflammatory parameters like IL-8, MCP-1, which are inhibited by TAT-Gap19 in our study.
In summary, this study demonstrates that Cx43 hemichannels play a role in radiation-induced endothelial oxidative stress, cell death, pro-inflammatory and pathological factors like IL-1B, IL-8, VCAM-1, MCP-1 and endothelin-1 and premature senescence. Further research is needed to investigate the underlying pathways and molecular mechanisms involved in Cx43 hemichannel opening in response to radiation exposure. This may open perspectives for the establishment of novel therapeutic strategies to protect from secondary radiotherapy side effects in thoracic cancer patients.
In conclusion, to the best of our knowledge, we show for the first time the involvement of endothelial Cx43 hemichannels in contributing to various radiation-induced processes, such as oxidative stress, cell death, inflammation and premature cell senescence that lead to endothelial activation and dysfunction, which is known as an early marker for atherosclerosis. Therefore, targeting Cx43 hemichannels with an inhibiting agent promises to therapeutically protect against radiation-induced endothelial cell damage.
The RBE4 (Rat Brain Endothelial) cell line was kindly provided by Dr F. Roux (Neurotech, Evry, France). The RBE4 cells were grown on collagen (rat-tail collagen; Roche diagnostics, Vilvoorde, Belgium) coated recipients in alfa-MEM+F10 (1/1) medium supplemented with 0.6% geneticin, 1% L-glutamax, 10% fetal bovine serum (FBS, Gibco, Invitrogen, Merelbeke, Belgium) and 1 ng/mL human recombinant basic fibroblast growth factor (hbFGF, Roche diagnostics). Cells plated for the radiation experiments were grown without hbFGF. Next to this cell line, also primary brain microvascular endothelial cells (pBMECs) isolated from C57BL6 and C57BL/6 Cx43fl/fl:Tie2-Cre mice, were used. Primary BMECs were grown in DMEM (Gibco, Invitrogen, Merelbeke, Belgium) supplemented with 20% Newborn Calf Serum (PAN Biotech, Aidenbach, Germany), 1% glutamax (Gibco, Invitrogen, Merelbeke, Belgium), 0.5% gentamicin (Gibco, Invitrogen, Merelbeke, Belgium), 1% vitamins, 2% amino acids and 1 ng/mL hbFGF; hbFGF was removed from the cultures 24 h prior to irradiation. Primary BMECs cultures were grown on plates coated with matrigel (3.5 μg/cm2). Patch clamp experiments were performed on HeLa cells stably transfected with Cx43, were cultured in Dulbecco's Modified Eagle's Medium (Invitrogen, Ghent, Belgium), supplemented with 10% FBS, 2 mM glutamine, 10 μg/ml streptomycin, 10 U/ml penicillin, 0.25 μg/ml fungizone (Invitrogen, Ghent, Belgium) and 1 μg/ml puromycin (Sigma-Aldrich, Bornem, Belgium). Hela-WT cells were grown in the medium without puromycin. Mouse Cx43 gene was cloned into the EcoRI/BamHI restricted cloning site of the expression vector pMJgreen. CytoMegalovirus (CMV) promoter was used. The vector also contains a puromycin N-acetyl-transferase (Pac) gene encoding region.
2′,6′-diamidino-2-phenylindole (DAPI), carbenoxolone (Cbx), N-acetyl-L-cystein (NALC), Pyridoxalphosphate-6-azopehyl-2′,4′-disolfonic acid (PPADS) and 4% formaldehyde were purchased from sigma-aldrich. 1.2-bis-(2-aminophynoxy)-ethane-N,N,N′,N′,tetraacetic acid acetoxy methyl ester (BAPTA-AM) originates from molecular probes (Invitrogen, Merelbeke, Belgium). Following connexin mimetic peptides were used: Gap26 (amino acids 64-76 from the first extracellular loop of Cx43, the sequence of which is shown in SEQ ID NO: 1) and TAT-gap19 (amino-acids 128-136 in the second half of the CL of Cx43, the sequence of which is shown in SEQ ID NO: 2) obtained from Genosphere biotechnologies (Genosphere biotechnologies, Paris, France) with a purity >85%.
Cortices, from 10-12 week old mice, were isolated by removing cerebellum, striatum, optic nerves, brain white matter, outer vessels and meninges. After homogenization with a Dounce homogenizer in WBB (Washing Buffer B: HMS, 10 mM Hepes, 0.35 g/L NaHCO3, 0.1% BSA), the homogenate was mixed with 30% dextran in WBB and centrifuged at 3000×g for 25 min at 4° C. The pellet containing the vascular component was then resuspended in WBB and filtered through a 60 μm NY60 Nylon Net Filter (Millipore, Darmstadt, Germany). Following centrifugation at 1000×g for 7 min at room temperature, the pellet was digested in collagenase/dispase supplement with DNase I (Roche Diagnostics, Vilvoorde, Belgium) and TLCK (Tosyl, Lysin chloromethyl ketone, sigma-aldrich) for 33 min at 37° C. in a shaking water bath. The digested capillary suspension was then seeded after multiple washing steps on wells coated with matrigel or glass coated with Corning Cell-Tak (VWR, Leuven, Belgium). For the isolation of intact capillaries the protocol was aborted just before the digestion step.
A defined area of the cell culture dishes were exposed to X-rays (1Gy or 20 Gy) by using a small animal radiation research platform (SARRP, Xstrahl, 220 kV, 13 mA), making use of a 3×3 mm collimator. Whole dish irradiation was done using a 10×10 cm broad-beam collimator, while localized Irradiation was performed with a 3×3 mm collimator. A Gafchromic RTQA2 film, with a sensitivity of 0.02 Gy, was placed underneath the cell dishes in order to delineate the irradiated zone. Control experiments with cells exposed to 0.02 Gy did not produce any detectable effect on the γ-H2AX scores (data not shown), excluding the possibility that scattered irradiation not detected by the irradiated film would influence the results in the bystander area.
Cells were fixed for 25 min with 4% formaldehyde (VWR) and blocked for 30 min with blocking buffer (5% normal goat serum, 1% bovine serum albumin (BSA), 0.2% Triton X-100 in PBS D+). Overnight incubation with primary antibody (1/500 anti-γ-H2AX in dilution buffer, 1/10 blocking buffer in PBS D+) was followed by a 1 h incubation with 1/400 XX-biotin-goat-anti-mouse antibody in dilution buffer, followed by a 1 h incubation with 1/400 streptavidin-alexa488 in PBS D+. Nuclei were stained with 1 μg/mL DAPI in PBS D+ for 10 min and cells were kept in PBS D+ supplemented with NaN3 at 4° C. All steps except the overnight incubation which was carried out at 4° C., were carried out at room temperature and cell cultures were rinsed thoroughly with PBS D+ between all incubation steps. Imaging was performed with an automated BD Pathway 435 imaging system (10× objective, 10×10 montage resulting in an overall image size of 8.5×6.5 mm). We then quantified the number of γ-H2AX-foci positive nuclei in the directly irradiated and bystander areas and expressed the count as a percentage relative to the number of nuclei and subtracted the percentage of background γ-H2AX signal in non-irradiated paired control cultures for each experiment. For counting γ-H2AX foci, images were thresholded to remove background pixel noise below the foci level. Where applicable, results were normalized against vehicle (bar charts with a 100% vehicle bar without statistical variability or a horizontal line).
We tested how counting γ-H2AX positive nuclei over a large surface area (9 and 55 mm2 for irradiated and non-irradiated zones respectively) was related to the more classical cell-based approach of quantifying the number of γ-H2AX foci per nucleus. To that purpose, we acquired high magnification (×63 objective) images and quantified the relative area occupied by γ-H2AX foci per nucleus in the irradiated zone. We found a linear relation between the low (×10 objective) and high magnification-based quantifications in the range of 0.1 to 1 Gy; at higher 10-20 Gy doses, the relation flattened (
Gamma-H2AX foci counts of
All γ-H2AX foci images (
RBE4 cells or pBMECs were seeded in 25 cm2 falcons or 8 cm2 petridishes. Lysates were made with RIPA (Cx43 and Cx37) and laemmli (Cx40) buffer. Protein concentration was determined using the BioRad DC protein assay kit (BioRad, Nazareth, Belgium). The lysate was separated by SDS-PAGE, over a mini-protean TGX stain free gel (BioRad, Nazareth, Belgium) and transferred to a nitrocellulose membrane (Amersham, Buckinghamshire, UK). Membranes were blocked in TBS supplemented with 5% (Cx43 and Cx40) or 2% non-fat milk (Cx37) and 1% (Cx43 and Cx40) or 0.05% (Cx37) Tween20. The following primary antibodies were used: rabbit-anti-Cx43 (sigma), rabbit-anti-Cx37 (anti-rat and anti-mouse), goat-anti-Cx40 (Santa Cruz) or rabbit-anti-β-tubulin antibody (Abcam, Cambridge, UK). Membranes were subsequently incubated with an alkaline phosphatase-conjugated goat anti-rabbit (Cx43, Cx37) or donkey anti-goat (Cx40) IgG antibody (sigma-aldrich). Detection was done using the nitro-blue-tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate reagent (NBT/BCIP kit, Zymed, Invitrogen). Total protein staining was carried out with SYPRO Ruby protein blot dye (Invitrogen, Molecular Probes, Merelbeke, Belgium).
For Cx immunoscytochemistry (Cx37, Cx40 and Cx37), fixation was as described for γ-H2AX immunostaining, followed by a 30 min (cell cultures) or 1 h (capillaries) blocking step with blocking buffer B (0.2% Tx100, 0.4% gelatin). Cells were incubated overnight with sheep anti-Cx37 (1/1000, Invitrogen), goat anti-Cx40 (1/50, Santa-Cruz) or rabbit anti-Cx43 (1/500), sigma) combined with rat anti-CD31 (combination of two antibodies, each 1/100, BD and Invitrogen) at 4° C. In a next step, secondary antibodies were administered for 1 h (donkey anti-sheep alexa 594, chicken anti-goat alexa 594, goat anti-rabbit alexa 594 and goat anti-rat alexa 488 respectively, each 1/400 in blocking buffer B).Confocal images were taken with a Leica SP8 X confocal microscope (×63 water immersion objective) and analyzed using Fiji software.
ATP was measured using a luciferin-luciferase assay kit (Sigma-Aldrich) in combination with a luminometer plate reader (Victor3 1420 multi label counter; Perkin Elmer, Zaventem, Belgium).
Extracellular ATP measurements were initially carried out at different time-points post-irradiation, the effect of blockers on ATP release was tested at the 5 min post-irradiation time-point (time of maximum ATP release).
Cells were grown to near confluency in 4-well plates. Cultures were incubated with 1 mM propidium iodide (PI) and 200 μM 10 kDa dextran-FITC before focal irradiation and dye uptake was measured 5 min post-irradiation by measuring the fluorescence intensity of both dyes following image acquisition with a BD pathway 435 imaging system.
Confluent monolayer cultures were washed three times with nominally calcium-free scrape loading and dye transfer (SLDT) buffer (137 mM NaCl, 5.36 mM KCl, 0.81 mM MgCl2.6H2O, 5.55 mM D-glucose, 25 mM Hepes, pH 7.4). Cells were incubated for 1 min in SLDT buffer containing 400 μM 6-carboxyfluorescein; a linear scratch (one per culture) was made across the cell layer using a syringe needle, and the cells were left for another minute in the same solution. Cultures were then washed six times with HBSS-HEPES and left for 15 min at room temperature, and images were taken as described for electroporation loading.
Subconfluent cultures of HeLa-Cx43 cells were seeded on 13 mm diameter glass coverslips (Knittel Glaser, Novolab, Geraardsbergen, Belgium) and experiments were performed at subconfluency the next day. Recordings were performed in the presence of extracellular Ca2+ and Mg2+ and under conditions of K+-channel blockade with Cs+, Ba2+ and TEA+. Cells were bathed in a recording chamber filled with a modified Krebs-Ringer solution, consisting of (in mM): 150 NaCl, 6 CsCl, 2 MgCl2, 2 CaCl2), 5 glucose, 5 HEPES, 1 BaCl2 and 2 pyruvate, with pH adjusted to 7.4. The whole-cell recording pipette solution was composed of (in mM): 130 CsCl, 10 NaAsp, 0.26 CaCl2), 5 HEPES, 2 EGTA, 5 TEA-Cl and 1 MgCl2, with an adjusted pH of 7.2. Free intracellular Ca2+ was 50 nM, as calculated with Webmax Standard software application (http://www.stanford.edu/˜cpatton/webmaxcS.htm). An EPC 7 PLUS patch clamp amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany) was used to perform single channel recordings. Data were acquired at 6 kHz using a NI USB-6221 data acquisition device from National Instruments (Austin, Tex., USA) and WinWCP acquisition software (designed by Dr. J. Dempster; University of Strathclyde, UK). All currents in whole-cell configuration were filtered at 1 kHz (7-pole Besselfilter). For single channel analysis, holding currents were subtracted from the recorded current traces, giving traces that only contained unitary current events. Unitary conductances were calculated from the elementary current transitions Δi as: γ=Δi/Vm. From these data, we constructed all-point conductance histograms that displayed one or more Gaussian distributions. These were fit by a probability density function assuming independent channel opening. Channel activity was quantified from the charge transfer Qm associated with unitary currents; this was done by integrating the unitary current traces (i.e., a function of time) over the duration of the voltage step as: Qm=∫idt.
Cells were seeded on glass coverslips (18 mm 0) coated with 3.5 μg/cm2 Corning cell-tak (VWR, Leuven, Belgium) and ester loaded for 45 min with 10 μM Fluo-3-AM in HBSS-HEPES supplemented with 1 mM of probenecid and 0.01% of pluronic F127 at room temperature followed by de-esterification over 15 min. Imaging was performed using an inverted fluorescence microscope equipped with a ×40 oil immersion objective and an EM-CCD camera (QuantEM™ 512SC CCD camera, Photometrics, Tucson, Ariz.). For direct Ca2+ measurements the loaded cells were irradiated and transferred to the microscopy stage. For medium transfer, the loaded cells were superfused for 1 min with HBSS-Hepes (1 mM), followed by 4 min with HBSS-Hepes conditioned by irradiated cultures. Fluorescence intensity changes in the cells were analyzed with custom-developed FluoFrames software (L. Leybaert, Ghent, Belgium). Ca2+ changes were quantified as the area under the curve (AUC) of the Ca2+ traces.
For ROS measurements, the cells were seeded in 96-well plates coated with collagen and irradiated using broad-beam at different doses. For ROS measurements the cells were loaded with 10 μM of CM-H2DCFDA in HBSS-Hepes. Imaging was performed with a BD Pathway 435 microscope equipped with an automated imaging focus system, avoiding ROS generation associated with long exposures to excitation. Results were corrected for the ROS produced in the irradiated medium alone.
To evaluate the amount of dead cells, RBE4 cells were seeded in 96-well plates coated with collagen and irradiated using broad-beam at different doses. The CytoTox-Glo™ Cytotoxicity assay (Promega, Madison, USA) was used following the manufacturers protocol. The CytoTox-Glo™ Cytotoxicity Assay uses a luminogenic peptide substrate, the AAF-Glo™ Substrate, to measure dead-cell protease activity, which is released from cells that have lost membrane integrity. Measurements were performed with aluminometer plate reader (Victor3 1420 multi label counter; Perkin Elmer, Zaventem, Belgium).
Cells were grown to near confluency on 4-well plates coated with collagen. Cell monolayer cultures were washed three times with HBSS-Hepes 25 mM (pH 7.2-7.4) and subsequently three times with a low conductivity electroporation buffer (4.02 mM KH2PO4, 10.8 mM K2HPO4, 1.0 mM MgCl2, 300 mM sorbitol, 2.0 mM Hepes, pH 7.4). They were placed 400 μm underneath a two-wire Pt-Ir electrode on the microscopic stage and electroporated in the presence of a tiny amount of electroporation solution (10 μl) containing 100 μg/mL SOD, 60 μM BAPTA or 20 μM BH4-Bcl2 combined with 100 μM 10 kDa DTR. Control cultures were electroporated with solution containing only 100 μM DTR vehicle solution. Electroporation was carried out with 50 kHz bipolar pulses applied as trains of 10 pulses of 2 ms duration each and repeated 15 times. The field strength was 100 V peak-to-peak applied over a 500 μm electrode separation distance. After electroporation, cells were thoroughly washed with HBSS-Hepes 25 mM followed by addition of CO2-independent medium (Invitrogen), which was was also present on the cultures during and following irradiation. The irradiated area was chosen away from the electroporation area (1555±1468 μm border-to-border distance; n=15) in order to investigate the effect of the blockers in the bystander area.
Data are expressed as mean±SEM, with ‘n’ denoting the number of independent experiments. Multiple groups were compared by one-way ANOVA and a Bonferroni post-test, using GraphPad Instat Software (Graphpad Software). P<0.05 was considered statistically significant. Statistical significance is indicated in the graphs by one symbol for P<0.05, two symbols for P<0.01 and three symbols for P<0.001.
1. X-Ray-Induced DNA Damage is Propagated from Irradiated to Non-Irradiated Bystander Cells in Microvascular Brain Endothelial Cells.
To investigate the role of connexin-mediated intercellular communication in radiation-induced bystander responses, we irradiated a defined area of adherent brain microvascular endothelial cell cultures. Both RBE4 cells, a rat brain microvascular endothelial cell line, as well as primary brain microvascular endothelial cells (pBMECs) isolated from mouse brains, grown to confluency, were used to that purpose. These cells express Cx37, Cx40 and Cx43 based on western blotting and immunocytochemical studies (
In a next experiment, we determined the kinetics of the γ-H2AX signal. Here, as in all other experiments discussed further, γ-H2AX quantification was done by counting γ-H2AX-positive nuclei, expressed relative to the total number of nuclei and background corrected by subtracting relative counts from non-irradiated paired control cell dishes (γ-H2AX count expressed as a percentage). Using this relative count, we observed a dose-dependent increase in γ-H2AX scores in the irradiated zone at 1-3 h after irradiation (at a 1 Gy dose, followed by a gradual recovery over the following 24 h time frame (
2. Gap Junction and/or Hemichannel Inhibitors Reduce γ-H2AX Scores in the Bystander Area
Paracrine factors and direct cell-cell communication via gap junctions are both critical in mediating bystander effects. As such, not only gap junctions, but also hemichannels, could contribute to the DNA damage propagation process. To investigate the contribution of gap junctions and hemichannels, we tested the effect of several connexin channel inhibitory substances: the general connexin channel blocker carbenoxolone (Cbx), Gap26 peptide that targets Cx43, Cx40 and Cx37 and rapidly inhibits hemichannel-related responses within minutes and gap junctions with longer exposures and TAT-Gap19 peptide, which blocks hemichannels composed of Cx43 with a half-time of 100 s, without inhibiting gap junctions. Cbx (50 μM), applied 30 min before 1 Gy irradiation and also present in the culture medium thereafter (30 min+3 h post-irradiation), significantly inhibited γ-H2AX-positive cell counts in the bystander zone while its effect in the irradiated zone was not statistically significant (RBE4 cultures;
We examined whether hemichannels open in response to X-ray exposure by using three different approaches: (i) measuring ATP-release in the supernatant, (ii) determining the cellular uptake of the hemichannel-permeable dye propidium iodide (PI), and (iii) patch clamp experiments. For ATP release, we irradiated RBE4 cells with a whole field broad-beam collimator and measured ATP 5 min post-irradiation. Both 1 and 20 Gy irradiation resulted in a significant increase in extracellular ATP compared to non-irradiated cultures and gradually returned to baseline non-irradiated levels within a 3 h time period (
4. X-Rays Induce Increases in Intracellular Ca2+ and ROS Production that Contribute to hemichannel opening in BMECs
Ionizing radiation has been shown to rapidly generate ROS as well as a rise of cytoplasmic Ca2+ ([Ca2+]i) which are two important triggers leading to the opening of hemichannels. We performed live cell [Ca2+ ]i imaging experiments starting 5 min after the exposure of RBE4 cells to broad-beam irradiation. Cells were loaded with the fluorescent Ca2+ indicator fluo-3-AM prior to irradiation with 1 or 20 Gy. These experiments demonstrated Ca2+ oscillatory activity in the cells, which significantly increased in percentage of oscillating cells and in number of oscillations per cell compared to non-irradiated controls (
In a second instance, RBE4 cells were pre-loaded with the oxidative stress marker CM-H2DCFDA-AM, after which the whole cell culture was exposed to X-rays at 1 or 20 Gy. Irradiation induced a significant and dose-dependent increase in signal intensity of the CM-H2DCFDA probe measured 5 min after irradiation (
Finally, a contribution of increases in [Ca2+ ]i and intracellular ROS production on hemichannel opening was investigated by recording the effect of BAPTA-AM (10 μM; 1 h pre-loading) and NALC (1 mM; 30 min pre-loading) on irradiation-induced ATP release. Both compounds significantly decreased ATP release in the supernatant 5 min after 1 Gy irradiation. A similar result was obtained by scavenging NO, a signaling molecule involved in the response to ionizing radiation as well as in hemichannel opening. Preloading of the cells with the NO-scavenger c-PTIO (100 μM; 30 min prior to 1 Gy irradiation) also strongly reduced irradiation-induced ATP release (
5. Interfering with Ca2±, ROS, NO or ATP Signaling Reduces Irradiation-Induced γ-H2AX Scores in Irradiated and Bystander Zones
To further document the role of Ca2+, ROS and NO signaling in the generation of γ-H2AX bystander effects, we applied BAPTA-AM, NALC and c-PTIO before focused irradiation (3×3 collimator) and analyzed their effect on γ-H2AX positive nuclei counts in the irradiated and bystander areas. These blocking reagents significantly reduced the γ-H2AX scores in both areas, most clearly in primary pBMEC cultures (
In addition to effects in the bystander area, some of the pharmacological blockers also had significant effects in the directly irradiated area (
The present results demonstrate that bystander communication of DNA damage, assessed by γ-H2AX quantification, involves connexin signaling via gap junctions and hemichannels, the canonical IP3/Ca2+ signaling cascade, extracellular ATP and ROS/NO signaling. Each of these signals have been implicated in radiation-induced bystander signaling, but a coherent framework is currently lacking. Of note, most of these signals play a role in cell-cell communication of Ca2+ signals and all of them have been linked to hemichannels, either as a trigger for their opening or as a substance released in a manner facilitated by hemichannels. Specifically, Ca2+ signal communication between cells is mediated by gap junctions that pass IP3 and Ca2+ and by paracrine signaling that involves extracellular ATP as well as NO released via various mechanisms that include hemichannel-related pathways. Below we discuss the present findings in the perspective of this Ca2+ signal communication framework.
Irradiation had dose-dependent effects on γ-H2AX scoring in the directly irradiated zone, while a saturation effect was observed in the bystander area (
IP3 diffusion through gap junctions was found to contribute to bystander signaling as demonstrated by the reduced γ-H2AX spreading in C6 glioma cells expressing IP3-impermeable Cx26 channels compared to those expressing WT Cx26; gap junctional coupling was furthermore maintained during the time frame of bystander spreading (
The irradiated cells showed clear oscillatory [Ca2+ ]i dynamics that play a role in hemichannel opening and ATP release. Blocking connexin channels furthermore strongly inhibited the [Ca2+]1 transient induced by medium transfer from irradiated cultures to recipient naive cultures (
All things considered, we propose that irradiation activates ATP-ROS-[Ca2+ ]i signaling with ROS as the primary generated signal, which, given its very short lifetime (10−9 sec for the hydroxyl radical) and diffusion distance (4 nm for the hydroxyl radical), has a limited role in long-range bystander consequences. Our results indicate that Ca2+ acts as an intracellular and ATP as an extracellular propagator of bystander effects. Both propagators diffuse but may also be actively regenerated, by Ca2+ activation of PLCs (e.g. PLCδ) followed by IP3 generation and subsequent store Ca2+ release, or by ATP-induced ATP release in Ca2+-dependent or independent ways. NO, which has an estimated diffusion distance in the order of 160 μm, may be involved in propagation but this needs to be balanced with the fact that low NO concentrations may also mitigate bystander effects. During propagation, extensive interactions will occur between these messengers as delineated higher, effectively assembling a robust signaling network governed by multiple actors inside and outside the cells linked by plasma membrane connexin channels either as hemichannels or gap junctions (
The blood-brain barrier is an essential part of the brain that shields the parenchymal neural tissue from the blood to create a well-controlled interstitial milieu that is adapted for optimal neuronal and glial functioning. It is formed by an extremely dense capillary network of brain blood vessels at the capillary level, in such a way that almost every neuron has a local capillary blood-brain barrier interface in its microenvironment. The blood-brain barrier shielding and brain-protecting functions are altered/disturbed in almost every brain disease, making it an essential player contributing to the pathophysiology of brain disease. Importantly, ionizing radiation induces breakdown of the blood-brain barrier through its effects on brain microvascular endothelial cells which are the most vulnerable cells in the brain in terms of their sensitivity to irradiation. As a result, disruption of the blood-brain barrier endothelial cell function is one of several pathophysiological elements considered to contribute to the cognitive alterations that occur after brain irradiation (e.g. in the context of brain tumor therapy). Here, we demonstrate that endothelial Cx43 knock-out prevents radiation-induced blood-brain barrier leakage. We performed in vivo irradiation experiments whereby a single brain hemisphere was irradiated with X-rays at a dose of 20 Gy. At various time points after irradiation, in a time window of up to 96 h, we injected 3 and 10 kDa fluorescent tracers after which the animals were sacrificed (tracers were 3 kDa dextran fluorescein and 10 kDa dextran Texas red). Then, we determined the leakage of the vascular fluorescent markers in the brain cortex. We found that the two fluorescent markers significantly leaked through the blood-brain barrier and appeared in the cortical parenchyma starting from 30 min up to 48 h after irradiation (
It is to be understood that although preferred embodiments, specific constructions and configurations, as well as materials, have been discussed herein for products according to the present invention, various changes or modifications in form and detail may be made without departing from the scope and technical teachings of this invention. For example, any formulas given above are merely representative of procedures that may be used. Functionality may be added or deleted from the block diagrams and operations may be interchanged among functional blocks. Steps may be added or deleted to methods described within the scope of the present invention.